Lips P
Department of Endocrinology, VU University Medical Center, P.O. Box 7057, 1007 MB Amsterdam, Netherlands.
Prog Biophys Mol Biol. 2006 Sep;92(1):4-8. doi: 10.1016/j.pbiomolbio.2006.02.016. Epub 2006 Feb 28.
Vitamin D3 is synthesized in the skin during summer under the influence of ultraviolet light of the sun, or it is obtained from food, especially fatty fish. After hydroxylation in the liver into 25-hydroxyvitamin D (25(OH)D) and kidney into 1,25-dihydroxyvitamin D (1,25(OH)2D), the active metabolite can enter the cell, bind to the vitamin D-receptor and subsequently to a responsive gene such as that of calcium binding protein. After transcription and translation the protein is formed, e.g. osteocalcin or calcium binding protein. The calcium binding protein mediates calcium absorption from the gut. The production of 1,25(OH)2D is stimulated by parathyroid hormone (PTH) and decreased by calcium. Risk factors for vitamin D deficiency are premature birth, skin pigmentation, low sunshine exposure, obesity, malabsorption and advanced age. Risk groups are immigrants and the elderly. Vitamin D status is dependent upon sunshine exposure but within Europe, serum 25(OH)D levels are higher in Northern than in Southern European countries. Severe vitamin D deficiency causes rickets or osteomalacia, where the new bone, the osteoid, is not mineralized. Less severe vitamin D deficiency causes an increase of serum PTH leading to bone resorption, osteoporosis and fractures. A negative relationship exists between serum 25(OH)D and serum PTH. The threshold of serum 25(OH)D, where serum PTH starts to rise is about 75nmol/l according to most surveys. Vitamin D supplementation to vitamin D-deficient elderly suppresses serum PTH, increases bone mineral density and may decrease fracture incidence especially in nursing home residents. The effects of 1,25(OH)2D and the vitamin D receptor have been investigated in patients with genetic defects of vitamin D metabolism and in knock-out mouse models. These experiments have demonstrated that for active calcium absorption, longitudinal bone growth and the activity of osteoblasts and osteoclasts both 1,25(OH)2D and the vitamin D receptor are essential. On the other side, bone mineralization can occur by high ambient calcium concentration, so by high doses of oral calcium or calcium infusion. The active metabolite 1,25(OH)2D has its effects through the vitamin D receptor leading to gene expression, e.g. the calcium binding protein or osteocalcin or through a plasma membrane receptor and second messengers such as cyclic AMP. The latter responses are very rapid and include the effects on the pancreas, vascular smooth muscle and monocytes. Muscle cells contain vitamin D receptor and several studies have demonstrated that serum 25(OH)D is related to physical performance. The active metabolite 1,25(OH)2D has an antiproliferative effect and downregulates inflammatory markers. Extrarenal synthesis of 1,25(OH)2D occurs under the influence of cytokines and is important for the paracrine regulation of cell differentiation and function. This may explain that vitamin D deficiency can play a role in the pathogenesis of auto-immune diseases such as multiple sclerosis and diabetes type 1, and cancer. In conclusion, the active metabolite 1,25(OH)2D has pleiotropic effects through the vitamin D receptor and vitamin D responsive elements of many genes and on the other side rapid non-genomic effects through a membrane receptor and second messengers. Active calcium absorption from the gut depends on adequate formation of 1,25(OH)2D and an intact vitamin D receptor. Bone mineralization mainly depends on ambient calcium concentration. Vitamin D metabolites may play a role in the prevention of auto-immune disease and cancer.
维生素D3在夏季受太阳紫外线照射时于皮肤中合成,或者从食物中获取,尤其是富含脂肪的鱼类。在肝脏中羟化成为25-羟基维生素D(25(OH)D),在肾脏中进一步羟化成为1,25-二羟基维生素D(1,25(OH)2D)后,这种活性代谢产物可进入细胞,与维生素D受体结合,随后与诸如钙结合蛋白基因等反应性基因结合。经过转录和翻译后形成蛋白质,例如骨钙素或钙结合蛋白。钙结合蛋白介导肠道对钙的吸收。甲状旁腺激素(PTH)刺激1,25(OH)2D的产生,而钙则使其减少。维生素D缺乏的危险因素包括早产、皮肤色素沉着、日照不足、肥胖、吸收不良和高龄。高危人群是移民和老年人。维生素D状况取决于日照情况,但在欧洲范围内,北欧国家血清25(OH)D水平高于南欧国家。严重的维生素D缺乏会导致佝偻病或骨软化症,此时新形成的骨样组织未矿化。不太严重的维生素D缺乏会导致血清PTH升高,进而导致骨吸收、骨质疏松和骨折。血清25(OH)D与血清PTH之间存在负相关关系。根据大多数调查,血清PTH开始升高时的血清25(OH)D阈值约为75nmol/l。对维生素D缺乏的老年人补充维生素D可抑制血清PTH,增加骨矿物质密度,并可能降低骨折发生率,尤其是在养老院居民中。在维生素D代谢存在遗传缺陷的患者和基因敲除小鼠模型中,对1,25(OH)2D和维生素D受体的作用进行了研究。这些实验表明,对于活性钙吸收、纵向骨生长以及成骨细胞和破骨细胞的活性,1,25(OH)2D和维生素D受体都是必不可少的。另一方面,高环境钙浓度,即高剂量口服钙或静脉补钙,可实现骨矿化。活性代谢产物1,25(OH)2D通过维生素D受体发挥作用,导致基因表达,例如钙结合蛋白或骨钙素的表达,或者通过质膜受体和第二信使如环磷酸腺苷发挥作用。后者的反应非常迅速,包括对胰腺、血管平滑肌和单核细胞的影响。肌肉细胞含有维生素D受体,多项研究表明血清25(OH)D与身体机能有关。活性代谢产物1,25(OH)2D具有抗增殖作用,并下调炎症标志物。1,25(OH)2D的肾外合成在细胞因子的影响下发生,对细胞分化和功能的旁分泌调节很重要。这可能解释了维生素D缺乏在自身免疫性疾病如多发性硬化症和1型糖尿病以及癌症的发病机制中可能起作用。总之,活性代谢产物1,25(OH)2D通过维生素D受体和许多基因的维生素D反应元件发挥多效性作用,另一方面通过膜受体和第二信使发挥快速的非基因组作用。肠道对活性钙的吸收取决于1,25(OH)2D的充分形成和完整的维生素D受体。骨矿化主要取决于环境钙浓度。维生素D代谢产物可能在预防自身免疫性疾病和癌症中发挥作用。